Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HRH2 | P25021 | 1/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20284100 | 0.87 | TLR7 (0.61) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL14592751 | 0.85 | TLR7 (0.56) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL20647740 | 0.84 | TLR7 (0.61) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL22803635 | 0.83 | TLR7 (0.65) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL13956155 | 0.83 | TLR7 (0.56) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL13937462 | 0.83 | TLR7 (0.56) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL3885227 | 0.83 | TLR7 (0.66) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL3177482 | 0.82 | TLR7 (0.64) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL15924735 | 0.82 | TLR7 (0.64) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL10587620 | 0.82 | TLR7 (0.64) | TLR7LMNAPOLBHRH2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284750-A1 | Immunoconjugate Synthesis Method | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| US-11110178-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200206357-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206357-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | TLR7 58/4885LMNA 4842/4885POLB 2398/4885 |
| US-20210284750-A1 | Immunoconjugate Synthesis Method | FCGR3B, FCGR1A, FCGR2A | TLR7 84/4885LMNA 1876/4885POLB 1569/4885 |
| US-11110178-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | TLR7 58/4885LMNA 4842/4885POLB 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.